FindTrial
Sign In

HPV DNA, E6/E7 mRNA expression, and p16INK4A immunohistochemistry in patients with nasopharyngeal cancer and other head and neck cancers: a retrospective study in China

HPV DNA, E6/E7 mRNA expression, and p16INK4A immunohistochemistry in patients with nasopharyngeal cancer and other head and neck cancers: a retrospective study in China

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400090824
Enrollment
Unknown
Registered
2024-10-14
Start date
2024-11-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head and neck cancer

Interventions

head and neck cancer patients:None

Sponsors

School of Public Health, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Individuals aged 18 years and above; 2. Only newly diagnosed cancer cases; 3. Patients with nasopharyngeal cancer and other head and neck cancers; 4. Diagnosis of nasopharyngeal cancer and other head and neck cancers will be based on the International Classification of Diseases 11th Revision (ICD-11)

Exclusion criteria

Exclusion criteria: Cancer cases in other skeletal and non-mucosal areas of the cheeks will be excluded.

Design outcomes

Primary

MeasureTime frame
HPV prevalence;P16 positive rate;E6/E7mRNA;DNA methylation.;—

Countries

China

Contacts

Public ContactHuachun Zou

School of Public Health, Fudan University

zouhuachun@fudan.edu.cn+86 139 2642 0419

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026